AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio

Spin-Out From UK’s Antibody Taskforce

The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.

AstraZeneca Cambridge
Following its COVID-19 success, AstraZeneca has created a new division to commercialize vaccines and antibody therapies. • Source: AstraZeneca

A new UK-based company, RQ Biotechnology, has emerged from stealth mode via a deal with AstraZeneca to license six early-stage COVID-19 monoclonal antibody candidates worth up to $157m plus royalties.

AstraZeneca already has its antibody combination Evusheld (tixagevimab and cilgavimab) on the market, and the new deal is a sign...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.